Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $136.5 million.

  • Beam Therapeutics' Operating Expenses rose 1302.94% to $136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $522.0 million, marking a year-over-year decrease of 194.06%. This contributed to the annual value of $479.1 million for FY2024, which is 1355.27% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Operating Expenses is $136.5 million, which was up 1302.94% from $128.6 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Operating Expenses registered a high of $200.4 million during Q1 2021, and its lowest value of $59.0 million during Q2 2021.
  • Over the past 5 years, Beam Therapeutics' median Operating Expenses value was $120.8 million (recorded in 2024), while the average stood at $119.4 million.
  • As far as peak fluctuations go, Beam Therapeutics' Operating Expenses surged by 60653.01% in 2021, and later tumbled by 5775.16% in 2022.
  • Over the past 5 years, Beam Therapeutics' Operating Expenses (Quarter) stood at $114.6 million in 2021, then decreased by 4.83% to $109.0 million in 2022, then skyrocketed by 68.16% to $183.3 million in 2023, then dropped by 29.03% to $130.1 million in 2024, then rose by 4.92% to $136.5 million in 2025.
  • Its last three reported values are $136.5 million in Q3 2025, $128.6 million for Q2 2025, and $126.8 million during Q1 2025.